Investor Relations

Corporate Overview

Myriad Genetics is a leading molecular diagnostic company dedicated to developing and marketing transformative tests which assess a person’s risk of developing disease, guide treatment decisions and help improve the quality of patient’s lives. Myriad’s portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual’s decision making process for monitoring and treating disease.

News Releases

Feb 2, 2012
Myriad's Prolaris(R) Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy

Jan 31, 2012
Myriad Genetics Reports Second Quarter Fiscal Year 2012 Results

View all releases »

Events & Presentations

Myriad Corporate Presentation

View all events & presentations »